Calidi Biotherapeutics, Inc. Annual Report: A Plain-English Guide

I’ve put together this guide to help you understand Calidi Biotherapeutics’ performance this year. My goal is to turn complex filing data into clear information so you can decide if this company fits your investment goals.

1. What does the company do?

Calidi Biotherapeutics is a biotech company currently in the research phase. They use stem cells to protect and deliver cancer-fighting viruses to tumor sites. By hiding these viruses from the patient’s immune system, Calidi aims to make cancer treatments more effective.

Because they are still researching, they have no products for sale yet. This year, they focused on advancing their Phase 1 clinical trial for a brain cancer treatment called CLD-101 and building their manufacturing capabilities.

2. Financial performance

Calidi is currently spending more than it earns. They reported a loss of about $34.5 million for the year ending December 31, 2024. With no revenue from product sales, their costs—$18.2 million for research and $12.3 million for general operations—far exceed their cash. To stay afloat, the company has raised money through private stock sales and debt agreements. These funds are used to pay for clinical trials and lab infrastructure.

3. Major wins and challenges

The company’s biggest win was merging with First Light Acquisition Group, which provided necessary capital. However, their main challenge is a constant need for more money. Throughout 2024 and early 2025, they issued various warrants. These agreements often include rules that force the company to issue more shares if the stock price drops. This creates a cycle where the company issues more stock to pay off debt, which reduces your ownership percentage in the company.

4. Financial health

Calidi’s financial situation is fragile. They have a working capital deficit and rely heavily on outside funding. As of the last report, they held about $4.2 million in cash, which is not enough to fund operations for the next 12 months without raising more money. Their financial structure is complex, with warrant values that change every quarter, causing swings in their reported profit or loss. While there were about 10.9 million shares outstanding in March 2026, this number changes frequently as debt is converted into new shares.

5. Key risks

The biggest risk is extreme dilution. Because the company relies on financing that creates more shares, your individual stake may shrink even if the company hits its goals. Auditors have noted that the company’s ongoing losses raise doubts about its ability to stay in business. Finally, if their clinical trials fail, they have no other products to fall back on, which could lead to a total loss of your investment.

6. Future outlook

The company’s roadmap focuses on reaching clinical milestones for their CLD-101 program. Success depends on securing more funding and achieving positive trial results. When reviewing their quarterly reports, keep a close eye on their "cash used in operations." If this remains high while cash levels stay low, it is a strong indicator that more stock sales are likely. Long-term success will likely depend on positive trial data and potential partnerships with larger drug companies.

Investor Tip: Before investing, ask yourself if you are comfortable with the high risk of dilution and the company's current reliance on continuous fundraising. If you decide to move forward, monitor their cash flow statements closely to see how long their current runway lasts.